Drug information
asuptegravir.m4a
| asuptegravir.m4a |
C22 H21 F2 N3 O5
(3S,7R)-N-[(2,4-difluorophenyl)methyl]-11-hydroxy-7-methyl-9,12-dioxospiro[4-oxa-1,8-diazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-6,1'-cyclopropane]-13-carboxamide
Asuptegravir is in Phase 3 development for HIV treatment.
(Compound details obtained from PubChem,1 Viruses article,2 Aidea Pharma website,3 and ClinicalTrials.gov4)
What is asuptegravir? What is asuptegravir?
What is asuptegravir?
Asuptegravir is an investigational drug that is being studied to treat HIV.3
Asuptegravir belongs to a group of HIV drugs called integrase inhibitors. Integrase inhibitors block an HIV enzyme called integrase. By blocking integrase, integrase inhibitors prevent HIV from multiplying and can reduce the amount of HIV in the body.
Asuptegravir may be effective against certain HIV strains that are resistant to other HIV drugs.2
To learn about how investigational drugs are tested during clinical trials, read the HIVinfo What is an Investigational HIV Drug? and HIV and AIDS Clinical Trials fact sheets.
Select clinical trials of asuptegravir Select clinical trials of asuptegravir
Select clinical trials of asuptegravir
Study Name: NCT06719310
Phase: 1b/2a
Status: This study has been completed.
Location: China
Purpose: The purpose of this study was to evaluate asuptegravir given by itself (monotherapy) and in combination with emtricitabine/tenofovir alafenamide in adults with HIV who have never received HIV medicines before. Researchers looked at 1) whether asuptegravir is safe and easy to tolerate, 2) how the body handles asuptegravir, and 3) how well asuptegravir works to reduce viral load in the body.5
Selected Study Results: Results were presented at the International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs (2025) and showed that asuptegravir was generally safe and well tolerated and could substantially reduce the amount of HIV in the participants’ blood.6
Study Name: NCT07711210
Phase: 1/2
Status: This study is currently ongoing, but not recruiting participants.
Location: China
Purpose: The purpose of this study is to see whether an antiretroviral regimen containing asuptegravir is safe and works to control viral load in adults who have received HIV medicines before and whose HIV is resistant to certain HIV medicines.7
Study Name: NCT07711223
Phase: 3
Status: This study is currently recruiting participants.
Locations: China
Purpose: The purpose of this study is to see whether asuptegravir plus emtricitabine/tenofovir alafenamide is safe and works to lower HIV levels in the blood in adults who have never received HIV medicines before.4
For more details on the studies listed above, see the Health Professional version of this drug summary.
Additional early-phase trials evaluating asuptegravir for HIV treatment have been completed, including a Phase 1a study (NCT06278389) that looked at various properties of asuptegravir in healthy adults, including how the body handles asuptegravir and whether asuptegravir is safe and easy to tolerate. Researchers also looked at how food affects the processing of asuptegravir in the body and drug-drug interactions. The study has been completed, and results were presented at the International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2025 (Abstract 32 and Abstract 33) and the Congress of the European Society of Clinical Microbiology and Infectious Diseases 2026 (Abstract P5206).8
What side effects might asuptegravir cause? What side effects might asuptegravir cause?
What side effects might asuptegravir cause?
One goal of HIV research is to identify safe new drugs that have fewer side effects. In the NCT06719310 study discussed under the previous section, asuptegravir was reported as being safe and well tolerated over the short study period. None of the participants discontinued asuptegravir because of side effects.5,6
Because asuptegravir is still being studied, information on possible side effects of the drug is not complete. As testing of asuptegravir continues, additional information on possible side effects will be gathered.
Where can I get more information about clinical trials studying asuptegravir? Where can I get more information about clinical trials studying asuptegravir?
Where can I get more information about clinical trials studying asuptegravir?
More information about asuptegravir-related research studies is available from ClinicalTrials.gov. (The ClinicalTrials.gov search can be modified so that you can get results that better match your interests.)
Some clinical trials may be looking for volunteer participants. Your health care provider can help you decide whether participating in a clinical trial is right for you. For more information, visit NIH Clinical Research Trials and You.
References
- National Center for Biotechnology Information. PubChem compound summary for CID 169913872, asuptegravir. Accessed October 23, 2026
- Ma MD, Luo RH, Li CY, et al. Anti-HIV-1 activity of the integrase strand transfer inhibitor ACC017. Viruses. 2025;18(1):33. doi:10.3390/v18010033. Accessed October 23, 2026
- Aidea Pharma website. Product pipeline. Accessed October 23, 2026
- Jiangsu Aidea Pharmaceutical Group Co., Ltd. A multicenter, randomized, double-blind, double-dummy, dolutegravir sodium tablets controlled, Phase III study to evaluate the efficacy and safety of ACC017 tablets in treatment-naïve adults with human immunodeficiency virus type 1 (HIV-1). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on July 7, 2026. NLM Identifier: NCT07711223. Accessed October 23, 2026
- Jiangsu Aidea Pharmaceutical Group Co., Ltd. A Phase Ib/IIa, randomized, double blinded, perallel, dosing ranging, placebo controled and proof of concept clinical trial to evaluate the safety, tolerability, PK and antiviral effect of ACC017 tablet as monotherapy/combination with NRTI in treatment naïve HIV-infected adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 26, 2024. NLM Identifier: NCT06719310. Accessed October 23, 2026
- Han N, Yang D, Wu L, et al. Antiviral activity, safety and PK/PD of ACC017 in antiretroviral naïve HIV-infected adults: a randomized, double-blind, placebo/dose-parallel-controlled short-term monotherapy study. Br J Clin Pharmacol. 2025;91(S1):16-16. doi:10.1002/bcp.70222. Accessed October 23, 2026
- Jiangsu Aidea Pharmaceutical Group Co., Ltd. Efficacy and safety of the ACC017-based antiretroviral regimen in treatment-experienced adults with HIV-1 harboring non-nucleoside reverse transcriptase inhibitor resistance mutations: a randomized, double-blind, placebo-controlled clinical trial. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on July 7, 2026. NLM Identifier: NCT07711210. Accessed October 23, 2026
- Jiangsu Aidea Pharmaceutical Group Co., Ltd. Study of single ascending dose, food effects and drug-drug interactions of ACC017 tablets in healthy adult participants in China: a single-center, randomized, double-blind, placebo-controlled, two-stage trial. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 23, 2024. NLM Identifier: NCT06278389. Accessed October 23, 2026
Last Reviewed: October 23, 2026